FORTIS - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 3.3

📊 Financial Health Snapshot

EPS (₹10.3) and PAT (₹226 Cr) — stable but modest profitability for a large-cap.

ROE (10.1%) & ROCE (12.0%) — slightly below high-efficiency benchmarks; decent but not outstanding.

Debt-to-Equity (0.28) — conservative leverage position, adding financial resilience.

Dividend Yield (0.12%) — negligible; signals growth orientation over shareholder payouts.

Quarterly Profit Variation (27.7%) — decent momentum, though not sustained quarter-on-quarter.

💰 Valuation Metrics Breakdown

Metric Value Interpretation

P/E Ratio 76.4 Extremely high — premium pricing vs. industry avg (69.2)

P/B Ratio ~7.21 Expensive compared to asset base

PEG Ratio 2.49 Indicates price exceeds near-term growth prospects

Intrinsic Value — Estimated range: ₹760–₹800 — current price slightly overvalued

📌 Valuation appears frothy — FORTIS is priced for perfection. Risk of correction if growth doesn't accelerate meaningfully.

🧵 Business Model & Strategic Positioning

Sector: Healthcare — hospital chains, diagnostics, and specialty care.

Moats

Strong brand and geographical reach with multiple facilities nationwide.

Increasing traction in medical tourism and specialty healthcare.

Risks

High valuation may limit upside.

Margins are sensitive to regulatory changes and operational costs.

Decline in FII holding (-0.22%) may signal cautious institutional sentiment.

📈 Technical Indicators & Entry Guidance

Current Price: ₹851

DMA 50 / 200: ₹773 / ₹678 — trending well above, shows bullish momentum

RSI (70.7): Overbought — potential reversal zone

MACD (21.3): Strong bullish momentum

Volume: Slightly below 1-week average — watch for participation confirmation

🛒 Suggested Entry Zone: ₹780–₹800 Avoid buying at peak RSI. Wait for pullback and consolidation toward DMA-50 before considering long positions.

🧭 Long-Term Holding Perspective

FORTIS is well-positioned within India's growing healthcare demand landscape. For a long-term thesis to hold water

Watch for sustained growth in high-margin services.

Expect expansion into Tier 2/3 markets and tech-enabled care.

Reassess if ROE doesn’t trend toward 13–15% within next fiscal cycles.

🔍 You might also explore peers like Apollo Hospitals or Narayana Health for a broader play on healthcare infrastructure. Want help building a diagnostic-to-hospital portfolio ladder? I’d love to sketch it out with you. 🩺📊

Edit in a page